Noticias y Actividades de Hepion Pharmaceuticals

Hepion Pharmaceuticals es una empresa que cotiza bajo el símbolo de cotización HEPA (US).

Fusión, adquisición y financiación con participación de Hepion Pharmaceuticals.

• Hepion Pharmaceuticals and Pharma Two B have announced they will merge  (publicado el 8 de agosto de 2024)..

Ver el organigrama con sus 5 ejecutivos principales

Biografías más buscadas en Hepion Pharmaceuticals

• Kaouthar Lbiati, Interim Chief Executive Officer
• Timothy Block, Director
• John Brancaccio, Chairman of the Board

Crear su alerta
para seguir los movimientos de los ejecutivos en Hepion Pharmaceuticals.

Hepion Pharmaceuticals tiene 1.913 competidores entre los que se incluyen Sanofi (Francia), Eli Lilly (Estados Unidos) y Moderna (Estados Unidos).

Popular M&A news in Farmacia

• Contraline acaba de anunciar una recaudación de fondos de 93 millones de dólares. (publicado el 3 de junio de 2026).
• Hims & Hers ha Eucalyptus adquirido (publicado el 2 de junio de 2026).
• Apotex ha presentado su expediente de OPI. Su símbolo de cotización será TSX. (publicado el 2 de junio de 2026).

Otros contactos sugeridos en el sector Farmacia

• Joaquin Duato - Chief Executive Officer and Chairman of the Board en Johnson & Johnson
• Richard Saynor - Chief Executive Officer en Sandoz
• Robert Ford - Chief Executive Officer and Chairman of the Board en Abbott

Saber más sobre el sector Farmacia

Últimos comunicados de prensa de Hepion Pharmaceuticals

• Hepion Pharmaceuticals In-Licenses ctRNA Biomarker Assay to Facilitate Early Diagnosis and Surveillance of Hepatocellular Carcinoma – Hepion Pharmaceuticals
• Hepion Pharmaceuticals Successfully Completes Application to the OTCQB – Hepion Pharmaceuticals
• Hepion Pharmaceuticals Announces Dr. Kaouthar Lbiati as Interim Chief Executive Officer – Hepion Pharmaceuticals
• Hepion Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq – Hepion Pharmaceuticals
• Hepion Pharmaceuticals Executes Binding Letter of Intent with New Day Diagnostics to Commercialize Diagnostic Tests for Celiac Disease, Respiratory Multiplex, H. Pylori and HCC – Hepion Pharmaceuticals
• Hepion Pharmaceuticals Announces Reverse Stock Split – Hepion Pharmaceuticals
• Hepion Pharmaceuticals Announces $9.0 Million Public Offering – Hepion Pharmaceuticals
• Hepion Pharmaceuticals, Inc. Announces Termination of Merger Agreement with Pharma Two B Ltd. – Hepion Pharmaceuticals
• Pharma Two B Announces Poster Presentation on P2B001 at the Annual Meeting of the Parkinson’s Disease Study Group – Hepion Pharmaceuticals
• Hepion Pharmaceuticals Issues Letter to Shareholders Urging Support for Proposed Merger with Pharma Two B – Hepion Pharmaceuticals
• View more press releases Close

Redes sociales sobre Hepion Pharmaceuticals

• Hepion Pharmaceuticals en Wikipedia, Google News y Yahoo Finance
• Hepion Pharmaceuticals en LinkedIn, Twitter y YouTube